Retrophin Bolsters Portfolio With Orphan Technologies Buyout

The rare disease-focused firm will pay $90m up front to acquire Orphan Technologies and its Phase I/II enzyme replacement therapy for homocystinuria. Earnouts up to $427m are possible as well.

Black Swan Event (face masks). Concept. A rare and unexpected event that has a major effect, such as a financial crash or pandemic. It is a metaphor often used in science or economics.
Deal adds to Retrophin's rare diseases pipeline

Retrophin, Inc. is turning to business development to build its rare disease-focused pipeline about a year after a Phase III failure threw its plans into disarray – the biotech has agreed to pay $90m up front with significant earnout potential to acquire privately held Orphan Technologies Ltd. and its enzyme replacement therapy candidate for homocystinuria (HCU).

The deal announced 22 October is expected to close before the end of 2020 and brings Retrophin Phase I/II OT-58,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.